Old Web
English
Sign In
Acemap
>
authorDetail
>
Michelle Liao
Michelle Liao
Massachusetts Institute of Technology
Pharmacokinetics
Germ cell
Biology
Cancer research
Poly ADP ribose polymerase
5
Papers
122
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.
2021
Journal of Clinical Oncology
Ecaterina Elena Dumbrava
Geoffrey I. Shapiro
Johanna C. Bendell
Timothy A. Yap
Rinath Jeselsohn
Denise M. Lepley
Sabrina Hurley
Kevin K. Lin
Michelle Liao
Jenn Habeck
Aaron S. Enke
Erika Hamilton
Show All
Source
Cite
Save
Citations (0)
Abstract 3027: Application of machine learning and grid search approaches to minimize lucitanib pharmacokinetic variability following different dosing regimens
2020
Cancer Research
Michelle Liao
Jessie Zhou
Mark Sale
Jim J. Xiao
Show All
Source
Cite
Save
Citations (0)
Abstract 3026: Evaluation of brain pharmacokinetics (PK) and tumor growth inhibition of PARP inhibitors in mouse xenograft models using semi-mechanistic PK/pharmacodynamic (PD) modeling
2020
Michelle Liao
Feng Jin
Minh Nguyen
Liliane Robillard
Andrew D. Simmons
Thomas Harding
Jim J. Xiao
Show All
Source
Cite
Save
Citations (0)
Dppa3 / Pgc7 / stellais a maternal factor and is not required for germ cell specification in mice
2004
Alex Bortvin
Mary L. Goodheart
Michelle Liao
David C. Page
Show All
Source
Cite
Save
Citations (0)
Dppa3 / Pgc7 / stella is a maternal factor and is not required for germ cell specification in mice
2004
BMC Developmental Biology
Alex Bortvin
Mary L. Goodheart
Michelle Liao
David C. Page
Show All
Source
Cite
Save
Citations (122)
1
map